05/25/2025
LOOK FOR THE RSV VACCINE TO BE OUT AT THE BEGINNING OF OCTOBER!
RSV hospitalizations in babies dropped by over 50% this year, proving that vaccines and antibody treatments are working — and saving lives.
New data from the CDC shows that the widespread availability of two RSV prevention tools has led to a dramatic drop in infant hospitalizations across the U.S. During the 2024–25 RSV season, hospitalization rates for babies under 8 months old fell by up to 46 percent compared to pre-pandemic seasons. The drop was even more pronounced in newborns under 2 months, where hospitalizations plummeted by more than half. The credit goes to a maternal RSV vaccine and nirsevimab, a long-acting antibody treatment for infants — both of which became widely available for the first time last fall.
Respiratory syncytial virus (RSV) is the leading cause of hospitalization in U.S. infants. With nearly every child contracting RSV by age two, severe cases can cause bronchiolitis or pneumonia, especially in the youngest babies.
The maternal vaccine provides early protection through transferred antibodies, while nirsevimab helps shield infants directly during the vulnerable first months. As uptake rose from 30% to 66% during the season, the benefits became clear. Researchers say these findings validate national guidelines and highlight the need for early and widespread access to these life-saving interventions.
learn more https://www.cdc.gov/mmwr/volumes/74/wr/mm7416a1.htm
